Compare NUS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | CGEM |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.4M | 671.7M |
| IPO Year | 1996 | 2021 |
| Metric | NUS | CGEM |
|---|---|---|
| Price | $10.19 | $12.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $28.00 |
| AVG Volume (30 Days) | 430.0K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $1,560,391,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $4.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.32 | $5.68 |
| 52 Week High | $14.62 | $13.60 |
| Indicator | NUS | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 65.27 |
| Support Level | $9.63 | $10.01 |
| Resistance Level | $10.18 | $12.88 |
| Average True Range (ATR) | 0.33 | 1.22 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 76.32 | 75.44 |
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.